5 July 2018 - Another press release from PHARMAC announcing the listing of a new medicine that should have occurred years ago and is only for patients with severe disease.

PHARMAC is pleased to provide another treatment option for patients with severe osteoporosis following the funding of denosumab, brand name Prolia, from 1 July 2018.

PHARMAC Director of Operations Lisa Williams says that denosumab will provide people with osteoporosis a chance of reducing injuries that can have a big impact on their daily lives.

“Funding this treatment will not only help patients with osteoporosis, but also reduce the burden on carers as well. More than 3000 people over three years are expected to benefit from this funding decision.”

Denosumab will be available to eligible people who have severe osteoporosis, are unable to take zoledronic acid as a treatment, and have tried other funded treatments and still experienced a fracture.

Read PHARMAC press release